BackElranatamab
Overview + Rationale
- B-cell maturation antigen (BCMA) is a tumor necrosis factor receptor superfamily member that is expressed predominantly on mature B cells
- BCMA mediates survival of antibody-secreting plasma cells after binding to its ligands BAFF (B-cell activating factor of the TNF family) and APRIL (a proliferation inducing ligand)
- In multiple myeloma, BCMA is widely expressed on malignant plasma cells
Mechanism of Action
Elranatamab bcmm is a bispecific B-cell maturation antigen (BCMA)-directed T-cell engaging antibody that binds BCMA on plasma cells, plasmablasts, and multiple myeloma cells and CD3 on T-cells leading to cytolysis of the BCMA-expressing cells. Elranatamab-bcmm activated T-cells caused proinflammatory cytokine release and resulted in multiple myeloma cell lysis.
Stage of Development
Elranatamab is being investigated as a single agent and in combination with other agent(s) in the following disease settings. The safety and efficacy of elranatamab for the uses listed below have not been established.
Relapsed/Refractory Multiple Myeloma
Phase 1B Combination
Phase 3 Monotherapy and Combination
Phase 3 Monotherapy and Combination
Newly Diagnosed Multiple Myeloma (Transplant Ineligible)
Phase 3 Combination
Newly Diagnosed Multiple Myeloma (Post-Transplant Maintenance)
Phase 3 Monotherapy
Multiple Myeloma Double –Class Exposed
Phase 3 Monotherapy and Combination